Ashwagandha for Cortisol: KSM-66 vs. Sensoril vs. Shoden

If you’ve read Cortisol Fix, you already know ashwagandha is one of the most well-studied adaptogens for stress and HPA axis support. But “well-studied” doesn’t mean “one-size-fits-all” — the research on ashwagandha has some real nuance to it, and not everyone is a good candidate for it. Here’s what the 2025–2026 research actually shows, which extract to choose, and who should steer clear.

What Is Ashwagandha, and Why Is It Different From a Stimulant

Ashwagandha (Withania somnifera) is a small shrub used in Ayurvedic medicine for thousands of years, sometimes called Indian ginseng or winter cherry. Its name translates roughly to “smell of horse,” a nod to both its earthy root scent and the traditional belief that it restores vigor. Its species name, somnifera, means “sleep-inducing” — which captures the paradox at the center of this herb: it’s used for both energy and calm, because as an adaptogen it doesn’t stimulate a single pathway. Instead, it helps the body regulate its stress response more efficiently, primarily through its effect on the HPA axis.

That distinction matters clinically. If a client is looking for a jolt of energy, ashwagandha is the wrong tool. If they’re dealing with a dysregulated stress response — the kind I write about extensively in Cortisol Fix — it’s one of the better-evidenced options available.

Beyond Cortisol: Other Evidence-Backed Benefits

Cortisol regulation gets most of the attention, but it’s not the only thing the clinical trial data supports. Here’s what else shows up consistently in the research — with an honest read on how strong each finding actually is:

• Anxiety. This has some of the more consistent trial data of any ashwagandha outcome. A 2025 meta-analysis of 15 RCTs (873 participants) found a significant reduction in anxiety on the Hamilton Anxiety Rating Scale (HAM-A) compared to placebo, and individual trials have shown HAM-A score reductions of roughly 59% versus a negligible change in the placebo group.⁴
• Sleep quality. Multiple RCTs using Sensoril and other extracts have shown improved sleep quality scores (PSQI) alongside stress and mood improvements, generally over 8–12 weeks of consistent use rather than as an immediate sedative effect.¹¹
• Testosterone and reproductive hormones in men. This is one of the more replicated secondary findings — trials have shown testosterone increases ranging from roughly 15% to 33% in men, alongside modest DHEA-S increases, likely reflecting a more balanced HPA-gonadal response rather than a direct androgenic effect.¹²
• Muscle strength and physical performance. Randomized trials in healthy adults have found improvements in muscle strength, recovery, and cardiorespiratory endurance with ashwagandha supplementation compared to placebo, which is part of why it’s increasingly used in sports nutrition contexts.¹³
• Menopausal symptoms. A 2026 randomized, placebo-controlled trial found ashwagandha root extract improved Menopause Rating Scale scores over 56 days, alongside changes in estradiol, LH, and FSH — a promising but still early area of research given the small trial size.¹⁴
• Inflammatory markers. A 2025 safety trial in older adults found a 51% reduction in CRP alongside stable liver and kidney markers over 180 days, suggesting an anti-inflammatory effect independent of its cortisol-lowering action, though this needs replication in more targeted inflammation studies rather than safety trials alone.¹⁵

The common thread: the anxiety, hormone, and safety data are genuinely solid at this point. The menopause and inflammation findings are promising but still resting on smaller or secondary-outcome data, so I’d treat those as “worth trying” rather than “clinically proven” until more dedicated trials are published.

How Ashwagandha Affects Cortisol: What the Research Actually Shows

The clearest, most consistent finding across the ashwagandha literature is its effect on serum cortisol. A 2025 systematic review and meta-analysis found a statistically significant reduction in cortisol levels compared to placebo, and this finding has been replicated across multiple independent meta-analyses through early 2026, with reductions in some individual trials reported in the range of 60–70%.¹

Here’s the nuance most marketing copy leaves out: cortisol reduction doesn’t always show up as a matching drop in perceived stress. A 2025 meta-analysis of eight randomized controlled trials in 488 adults found that while ashwagandha reliably reduced cortisol, it did not significantly reduce Perceived Stress Scale (PSS) scores compared to placebo.² A separate 2026 dose-response meta-analysis reached a similar conclusion, noting the disconnect between biochemical and subjective outcomes likely reflects methodological differences — including that most trials don’t control for the circadian rhythm of cortisol secretion or meal-induced cortisol release.³

What this means practically: ashwagandha is genuinely effective at lowering the hormone, but “I feel calmer” isn’t guaranteed to follow immediately, and effects generally build over 4–8 weeks rather than same-day. Individual randomized trials that also tracked anxiety using the Hamilton Anxiety Rating Scale (HAM-A) have shown more consistent subjective improvement than the PSS studies, along with modest increases in DHEA-S and testosterone in men — additional markers of a more balanced HPA-gonadal response.⁴

KSM-66 vs. Sensoril vs. Shoden: Which Extract Should You Choose

Not all ashwagandha is created equal, and this is where most consumers get lost. The three branded, clinically studied extracts differ in plant part used, withanolide concentration, and clinical focus:

In practice, KSM-66 tends to be the more “uplifting” and balanced of the three, Sensoril leans more sedating and is often a better fit for someone whose main complaint is racing thoughts at night, and Shoden lets you get a full clinical dose from a smaller capsule or lower powder amount, which matters if pill burden is a concern for a client. All three have double-blind, placebo-controlled human trials behind them, which is more than can be said for most generic ashwagandha powders on the market.

Clinical Dosing: What the Studies Actually Used

Doses vary by extract because withanolide concentration varies so much between them:

• KSM-66: 300–600 mg daily, once or split into two doses, is the range used in most positive stress and cortisol trials.
• Sensoril: 125–250 mg daily has been studied for stress, anxiety, and sleep quality outcomes.
• Shoden: 120 mg daily (delivering roughly 42 mg of withanolides) has shown effects comparable to much higher doses of the lower-concentration extracts in comparative testing.

Most trials ran 8–12 weeks, and a 2025 safety study following 191 adults on KSM-66 for a full 12 months found no clinically significant changes in liver, kidney, or thyroid function, with cortisol modestly declining and testosterone significantly increasing over the study period.⁵ That’s reassuring for longer-term use in appropriate candidates, though most clinicians still recommend periodic reassessment rather than indefinite, unsupervised use.

Safety, Contraindications, and Who Should Avoid Ashwagandha

This is the section I wish got more attention in ashwagandha content, because the “it’s just an herb” framing glosses over some real contraindications.

Ashwagandha is a nightshade. It belongs to the Solanaceae family — the same botanical family as tomatoes, potatoes, and peppers. If you’ve read my post on nightshade sensitivity or if a client has tested sensitive to nightshades on MRT/LEAP, ashwagandha is a reasonable candidate to screen for reactivity rather than assume is automatically safe just because it’s marketed as a wellness herb.

Thyroid conditions are a significant caution. Ashwagandha can directly stimulate thyroid hormone production, raising T3 and T4 while lowering TSH. This can be desirable in some cases of subclinical hypothyroidism under supervision, but it is genuinely risky for anyone with hyperthyroidism, Graves’ disease, or thyroid nodules, where it can precipitate thyrotoxicosis. Case reports exist of previously healthy adults developing clinical thyrotoxicosis after starting or increasing an ashwagandha dose.⁶

Autoimmune conditions warrant caution — but the evidence here is more nuanced than most sites let on. Ashwagandha has documented immune-stimulating activity (increased lymphocyte activity and cytokine production), and this is the mechanism cited whenever ashwagandha is flagged as a potential trigger for autoimmune flares. A 2025 systematic scoping review in Lupus Science & Medicine specifically names ashwagandha among a group of “immunostimulatory” herbal supplements — including elderberry, spirulina, and echinacea — associated with flares in autoimmune skin conditions.⁷ A related study of herbal supplement use in dermatomyositis and cutaneous lupus patients found that 31% of dermatomyositis patients and 10% of cutaneous lupus patients who used an immunostimulatory herbal supplement experienced a flare or new-onset disease afterward — though ashwagandha was one of the less-frequently-used supplements in that group, and elderberry drove most of the signal, so it wasn’t isolated with its own reliable flare rate.⁸ There’s also an individual case report of an optic neuritis flare (later diagnosed as MS) temporally associated with ashwagandha use, though the authors’ own causality scoring rated the link “possible” rather than definite, and they noted the broader literature on ashwagandha in autoimmune disease is genuinely conflicting.⁹

Here’s the part that rarely makes it into the “avoid if autoimmune” warnings: animal models of rheumatoid arthritis and lupus have actually shown ashwagandha reducing disease activity, by suppressing autoreactive T cells and inflammatory cytokines rather than provoking them.¹⁰ No randomized controlled trial has tested ashwagandha in an autoimmune population with flares as an endpoint, in either direction. So the honest summary is: ashwagandha’s immune effects are genuinely bidirectional and context-dependent, the caution for autoimmune conditions is grounded in real case reports and a plausible mechanism rather than being purely theoretical, but it also isn’t the settled, one-directional risk that a lot of blanket “avoid if autoimmune” warnings imply. For a client with an active autoimmune condition, this is squarely a “discuss with your rheumatologist or endocrinologist and monitor closely if you proceed” situation, not an automatic green or red light.

Pregnancy and breastfeeding: Ashwagandha isn’t well studied in pregnancy, and it has documented abortifacient properties in excess amounts, particularly a concern in the first trimester. It’s generally advised to avoid it during pregnancy and lactation.

Liver considerations: Rare case reports of ashwagandha-induced hepatic injury exist, generally resolving after discontinuation. Anyone with pre-existing liver disease should use it only under medical supervision, and periodic liver panel monitoring is a reasonable precaution for longer-term use in any client.

Medication interactions: Ashwagandha can potentiate sedatives, thyroid medications, diabetes medications, and blood pressure medications, and is generally recommended to be discontinued two weeks prior to any scheduled surgery due to its central nervous system effects.

Stacking Ashwagandha With Other Cortisol Support

For clients whose testing and history make them good candidates, ashwagandha pairs mechanistically well with a couple of other tools I use often:

• Magnesium glycinate — where ashwagandha works top-down through the HPA axis, magnesium glycinate works bottom-up, replenishing magnesium that’s often depleted by chronic cortisol exposure and supporting GABA activity directly. See my full comparison in Magnesium L-Threonate vs. Glycinate for which form fits which goal.
• L-theanine — pairs well for the “calm but not sedated” daytime window, particularly for clients who find ashwagandha alone too sedating during work hours.

My Take: Which Ashwagandha Extract I’d Recommend

For most healthy adults without the contraindications above, I lean toward extracts with real clinical trial data behind the specific branded ingredient rather than a generic “ashwagandha root powder” with no standardization. Nootropics Depot carries all three major clinically studied extracts, third-party lab tested, in both capsule and powder form:

• KSM-66 Ashwagandha — my go-to starting point for most clients; well-balanced, extensively studied, and generally well tolerated.
• Sensoril Ashwagandha — worth considering if sleep quality and evening wind-down are the primary goal.
• Shoden Ashwagandha — a good option for anyone who wants a full clinical dose in a smaller capsule.

As always, “test not guess” applies here too — a full thyroid panel and a conversation about autoimmune history should come before starting ashwagandha, not after.

Frequently Asked Questions

Does ashwagandha have benefits beyond lowering cortisol?
Yes. The strongest secondary evidence is for anxiety reduction (measured by the Hamilton Anxiety Rating Scale) and increased testosterone in men. There’s also good trial data for improved sleep quality and muscle strength/recovery. Evidence for menopausal symptom relief and anti-inflammatory effects is promising but comes from smaller or secondary-outcome studies, so it’s less firmly established than the cortisol and anxiety findings.

Does ashwagandha actually lower cortisol?
Yes. Multiple 2025 and 2026 meta-analyses of randomized controlled trials confirm ashwagandha significantly reduces serum cortisol compared to placebo. However, this biochemical change doesn’t always translate to a measurable reduction in perceived stress scores in every study.

Which is better, KSM-66 or Sensoril?
Neither is universally “better” — they’re suited to different goals. KSM-66 is the most researched and tends to feel more balanced and uplifting, while Sensoril is more calming and is often preferred for sleep support and higher perceived stress.

Can I take ashwagandha if I have a thyroid condition?
This requires caution and medical supervision. Ashwagandha can raise T3 and T4 while lowering TSH, which may help some cases of subclinical hypothyroidism but can be risky for hyperthyroidism, Graves’ disease, or autoimmune thyroid conditions like Hashimoto’s. Anyone with a thyroid condition should talk to their provider before starting.

Is ashwagandha safe to take long-term?
A 12-month safety study on KSM-66 found no significant changes in liver, kidney, or thyroid function in healthy adults. That said, most clinicians recommend periodic reassessment rather than indefinite unsupervised use, especially given ashwagandha’s nightshade classification and thyroid-modulating effects.

Can I take ashwagandha if I have an autoimmune condition?
It depends, and the evidence is more mixed than the blanket “avoid it” warnings suggest. Ashwagandha has documented immune-stimulating activity, and a 2025 systematic review flagged it among several herbs associated with flares in autoimmune skin conditions, alongside case reports of flares in other autoimmune contexts. But animal studies have also shown it suppressing autoreactive immune activity in models of lupus and rheumatoid arthritis, and no controlled trial has tested it in autoimmune patients specifically. This is a genuine “discuss with your specialist and monitor closely” situation rather than a clear yes or no.

Is ashwagandha a nightshade?
Yes. Ashwagandha belongs to the Solanaceae (nightshade) family, along with tomatoes, potatoes, and peppers. Anyone with a known nightshade sensitivity, including those identified through MRT/LEAP testing, should treat ashwagandha as a potential trigger rather than assume it’s automatically tolerated.